IP Library › Granted Patent US 12,233,073
Granted Patent B2
US 12,233,073 · App. 16/620,382 · Granted Feb 25, 2025

Skin care formulations and skin cancer treatment

Inventors: Ann M. Bode (Cannon Falls, MN); Zigang Dong (Austin, MN); Eunmiri Roh (Austin, MN)
Assignee: Regents of the University of Minnesota
A61K31/573A61K9/0014A61K31/58A61P35/04A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,233,073
App. No.
16/620,382
Granted
Feb 25, 2025
Kind
B2
Abstract

An example technique for treating a skin cancer condition includes administering a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to a patient having skin cancer or having a high risk of developing skin cancer. An example composition includes a therapeutically effective amount of a PRPK inhibitor for treating a skin cancer condition. An example composition includes a pharmaceutically effective amount of at least one anti-solar ultraviolet (anti-sUV) combination for preventing a skin cancer condition. The at least one anti-sUV combination is chosen from the combinations: avobenzone and octinoxate; octocrylene and zinc oxide; avobenzone, octocrylene, and titanium dioxide; or avobenzone, octocrylene, and zinc oxide.

Claims (20)

1. A method for treating a skin condition, the method comprising administering a composition comprising a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to a patient having skin cancer or having a high risk of developing skin cancer, wherein the composition comprises 0.1% to 1% (weight/volume) of the PRPK inhibitor, and wherein the PRPK inhibitor comprises rocuronium bromide or analogs thereof.

2. The method of claim 1 , wherein the skin cancer condition comprises one or more of actinic keratosis, squamous cell carcinoma, or basal cell carcinoma.

3. The method of claim 1 , wherein the skin cancer condition is associated with T-LAK cell-originated protein kinase (TOPK)-dependent PRPK phosphorylation.

4. The method of claim 1 , further comprising comparing the concentration of phosphorylated PRPK (p-PRPK) in a first biological sample of the patient obtained prior to the administration of the PRPK inhibitor and in a second biological sample of the patient obtained after the administration of the PRPK inhibitor.

5. The method of claim 4 , wherein a lower concentration of p-PRPK in the second biological sample compared to the concentration of p-PRPK in the first biological sample is indicative of inhibition of PRPK phosphorylation by the PRPK inhibitor.

6. The method of claim 4 , further comprising adjusting a dosage of the PRPK inhibitor administered to the patient based on the comparison.

7. The method of claim 1 , wherein the patient is administered at least 0.1 mg/day, 1 mg/day, 5 mg/day, 10 mg/day, 20 mg/day, 50 mg/day, or 100 mg/day of the PRPK inhibitor.

8. The method of claim 1 , wherein the PRPK inhibitor comprises the rocuronium bromide and betamethasone 17-valerate, or analogs thereof.

9. The method of claim 1 , wherein the administering the PRPK inhibitor comprises administering a pharmaceutically acceptable carrier including the PRPK inhibitor to the patient.

10. The method of claim 9 , wherein the pharmaceutically acceptable carrier comprises a topical formulation including the PRPK inhibitor.

11. The method of claim 1 , further comprising administering at least another treatment comprising one or more of chemotherapy, immunotherapy, radiation therapy, DNA therapy, RNA therapy, nanotherapy, adjuvant therapy, viral therapy, photodynamic therapy, electrocautery, laser therapy, or surgery.

12. The method of claim 1 , wherein a therapeutic effect is obtained by administering the PRPK inhibitor, wherein the therapeutic effect comprises one or more of: a reduction or a stability in one or more of an average volume of lesions, an average number of lesions, an average volume of tumors, an average number of tumors, or partial remission, complete remission, or metastasis.

13. The method of claim 1 , wherein the skin condition comprises actinic keratosis.

14. The method of claim 1 , wherein the skin condition comprises precursor condition to cutaneous squamous cell carcinoma.

15. The method of claim 1 , wherein administering the composition comprising the therapeutically effective amount of the PRPK inhibitor to the patient comprises administering a lotion comprising the therapeutically effective amount of the PRPK inhibitor to the patient.

16. A method for treating a skin condition, the method comprising administering a composition comprising a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to a patient having actinic keratosis, wherein the composition comprises 0.1% to 1% (weight/volume) of the PRPK inhibitor, and wherein the PRPK inhibitor comprises rocuronium bromide or analogs thereof.

17. The method of claim 16 , wherein administering the composition comprising the therapeutically effective amount of the PRPK inhibitor to the patient comprises administering a lotion comprising the therapeutically effective amount of the PRPK inhibitor to the patient.

18. The method of claim 17 , wherein the lotion comprises a salt of ethylenediamine tetra-acetic acid, 1,3-butylene glycol, glycerin, pentylene glycol, cetyl alcohol, glyceryl stearate, and hydrogenated polydecene.

19. The method of claim 1 , wherein the composition comprises an oil in water emulsion.

20. The method of claim 19 , wherein the oil in water emulsion comprises a salt of ethylenediamine tetra-acetic acid, 1,3-butylene glycol, glycerin, pentylene glycol, cetyl alcohol, glyceryl stearate, and hydrogenated polydecene.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2022
From: DONG, ZIGANG
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 061886/0364 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2022
From: ROH, EUNMIRI; BODE, ANN M
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 061383/0926 →
Continuity (3)
Provisional Application 62517257 · Jun 9, 2017
Provisional Application 62517319 · Jun 9, 2017
Related Publication 20200179404A1 · Jun 11, 2020
References Cited (80)
US 4789667A · Makino et al. · 1988 [cited by applicant]
US 6015548A · Siddiqui · 2000 [cited by applicant]
US 6090369A · Stewart · 2000 [cited by applicant]
US H2043H · Deckner · 2002 [cited by applicant]
US 7915243B2 · Puglia et al. · 2011 [cited by applicant]
US 8048456B2 · Burke-Colvlin et al. · 2011 [cited by applicant]
US 8071578B2 · Sefton · 2011 [cited by applicant]
US 9056063B2 · Hanson · 2015 [cited by applicant]
US 9278061B2 · Florence · 2016 [cited by applicant]
US 9937119B2 · Mendoza et al. · 2018 [cited by applicant]
US 10105357B2 · Chen et al. · 2018 [cited by applicant]
US 10500152B2 · Gan et al. · 2019 [cited by applicant]
US 20030027776A1 · Roschke · 2003 [cited by applicant]
US 20060069055A1 · Dajee · 2006 [cited by examiner]
US 20060251598A1 · Ramirez et al. · 2006 [cited by applicant]
US 20090247477A1 · Talalay et al. · 2009 [cited by applicant]
US 20090258841A1 · Murphy · 2009 [cited by applicant]
US 20110044920A1 · Hines et al. · 2011 [cited by applicant]
US 20110064832A1 · Burke-Colvin et al. · 2011 [cited by applicant]
US 20110269699A1 · Keegan et al. · 2011 [cited by applicant]
US 20110319277A1 · Park et al. · 2011 [cited by applicant]
US 20120015064A1 · Burke-Colvin et al. · 2012 [cited by applicant]
US 20120128606A1 · Igiebor · 2012 [cited by applicant]
US 20130315846A1 · Collier et al. · 2013 [cited by applicant]
US 20140161746A1 · Ramirez et al. · 2014 [cited by applicant]
US 20150045289A1 · West et al. · 2015 [cited by applicant]
US 20150250709A1 · Gan et al. · 2015 [cited by applicant]
US 20150290121A1 · Gurge · 2015 [cited by applicant]
US 20150313819A1 · Edelson · 2015 [cited by applicant]
US 20150328098A1 · Soroudi · 2015 [cited by applicant]
US 20160015813A1 · Gan et al. · 2016 [cited by applicant]
DE 2633556A · 1977 [cited by examiner]
DE 202015001779U1 · 2015 [cited by applicant]
DE 202014010806U1 · 2016 [cited by applicant]
EP 2266527A2 · 2010 [cited by applicant]
EP 2255781B1 · 2012 [cited by applicant]
WO 1991007166 · 1991 [cited by applicant]
WO 1997046219A1 · 1997 [cited by applicant]
WO 2011046771 · 2011 [cited by applicant]
WO 2015030702A2 · 2015 [cited by applicant]
WO 2016062285 · 2016 [cited by applicant]
WO WO2016062285A1 · 2016 [cited by examiner]
WO 2016090247 · 2016 [cited by applicant]
WO 2016090252A1 · 2016 [cited by applicant]
Clement et al., The use of the hairless mouse to develop topical cytostatic combination chemotherapy, 1984, Clinical and Experimental Dermatology, vol. 9, pp. 127-138. (Year: 1984). [cited by examiner]
Singal et al., Facial Basal Cell Carcinoma Treated with Topical 5% Imiquimod Cream with Dermoscopic Evaluation, Jun. 15, 2016, Journal of Cutaneous and Aesthetic Surgery, vol. 9 iss. 2, pp. 122-125. (Year: 2016). [cited by examiner]
Misago et al., Sebaceous carcinoma in association with actinic keratosis: Areport of two cases with an immunohistochemical study, Mar. 21, 2015, The Journal of Dermatology, vol. 42, pp. 616-620. (Year: 2015). [cited by examiner]
Atzmony et al., “Treatments for Cutaneous Lichen Planus: A Systematic Review and Meta-Analysis,” American Journal of Clinical Dermatology, vol. 17, No. 1, Feb. 2016, 13 pp. [cited by applicant]
Berg et al., “Skin Cancer in Organ Transplant Recipients: Epidemiology, Pathogenesis, and Management,” Journal of the American Academy of Dermatology, vol. 47, No. 1, Jul. 2002, 20 pp. [cited by applicant]
Brash et al., “Sunlight and Sunburn in Human Skin Cancer: p53, Apoptosis, and Tumor Promotion,” Journal of Investigative Dermatology Symposium Proceedings., vol. 1, No. 2, Apr. 1996, 7 pp. [cited by applicant]
Edlund et al., “Data-Driven Unbiased Curation of the TP53 Tumor Suppressor Gene Mutation Database and Validation by Ultradeep Sequencing of Human Tumors,” Proceedings of the National Academy of Sciences of the United St… [cited by applicant]
Facchin et al., “Phosphorylation and activation of the atypical kinase p53-related protein kinase (PRPK) by Akt/PKB,” Cellular and Molecular Life Sciences, vol. 64, Aug. 2007, 10 pp. [cited by applicant]
Ferrone et al., “Clinicopathological features of and risk factors for multiple primary melanomas,” Journal of the American Medical Association (JAMA), vol. 294, No. 13, Oct. 2005, 8 pp. [cited by applicant]
Giles et al., “Multiple primary melanomas: an analysis of cancer registry data from Victoria and New South Wales,” Melanoma Research, vol. 5, No. 6, Dec. 1995, 6 pp. [cited by applicant]
Hensler et al., “Inflammation and Skin Cancer: Old Pals Telling New Stories,” Cancer Journal, vol. 19, No. 6, Nov./Dec. 2013, 8 pp. [cited by applicant]
Jemal et al., “Cancer statistics, 2010,” CA Cancer J. Clin, vol. 60, No. 5, Sep./Oct. 2010, 24 pp. [cited by applicant]
Jung et al., “Myricetin Inhibits UVB-Induced Angiogenesis by Regulating PI-3 Kinase in vivo,” Carcinogenesis, vol. 31, No. 5, May 2010, 7 pp. [cited by applicant]
Jung et al., “Myricetin Suppresses UVB-Induced Skin Cancer by Targeting Fyn,” Cancer Research, vol. 68, No. 14, Jul. 2008, 9 pp. [cited by applicant]
Jung et al., “Myricetin suppresses UVB-induced wrinkle formation and MMP-9 expression by inhibiting Raf,” Biochemical Pharmacology, vol. 79, No. 10, May 2010, 7 pp. [cited by applicant]
Jung et al., “Naringenin targets ERK2 and suppresses UVB-induced photoaging,” Journal of Cellular Molecular Medicine, vol. 20, No. 5, May 2016, 11 pp. [cited by applicant]
Kim et al., “Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth,” Cancer Research, vol. /2, No. 12, Jun. 2012, 9 pp. [cited by applicant]
Lanigan et al., “Final report on the Safety Assessment of EDTA, Calcium Disodium EDTA, Diammonium EDTA, Dipotassium EDTA, Disodium EDTA, TEA-EDTA, Tetrasodium EDTA, Tripotassium EDTA, Trisodium Edta, Hedta, and Trisodiu… [cited by applicant]
Lee et al., “5-Deoxykaempferol Plays a Potential Therapeutic Role by Targeting Multiple Signaling Pathways in Skin Cancer,” Cancer Prevention Research, vol. 3, No. 4, Apr. 2010, 13 pp. [cited by applicant]
Lee et al., “Myricetin is a Novel Natural Inhibitor of Neoplastic Cell Transformation and MEK1,” Carcinogenesis, vol. 28, No. 9, Sep. 2007, 10 pp. [cited by applicant]
Lim et al., “MLK3 is a Direct Target of Biochanin A, which Plays a Role in Solar UV-Induced COX-2 Expression in Human Keratinocytes,” Biochemical Pharmacology, vol. 86, No. 7, Oct. 2013, 18 pp. [cited by applicant]
Lim et al., “The daidzein metabolite, 6,7,4′-Trihydroxyisoflavone, is a Novel Inhibitor of PKCalpha in Suppressing Solar UV-induced Matrix Metalloproteinase 1,” International Journal of Molecular Sciences, vol. 15, No. … [cited by applicant]
Lu et al., “Tumorigenic Effect of Some Commonly Used Moisturizing Creams When Applied Topically to UVB-pretreated High-Risk-Mice,” Journal of Investigative Dermatology, vol. 129, No. 2, Aug. 2008, 8 pp. [cited by applicant]
Luxen et al., “[Rocuronium and sugammadex in emergency medicine: requirements of a muscle relaxant for rapid sequence induction],” Der Anaesthesist, vol. 63, No. 4, Apr. 2014, 7 pp. (Translation provided for only the Ab… [cited by applicant]
Marcil et al., “Risk of Developing a Subsequent Nonmelanoma Skin Cancer in Patients With a History of Nonmelanoma Skin Cancer: A Critical Review of the Literature and Meta-analysis,” Archives of Dermatology, vol. 136, N… [cited by applicant]
Marshall et al., “Research and development of aminosteroid neuromuscular blocking agents: past and future,” European Journal of Anaesthesiology, vol. 12, Supplement 11, Aug. 1995, 6 pp. [cited by applicant]
McMeniman et al., “Risk factors in a cohort of patients with multiple primary melanoma,” Australasian Journal of Dermatology, vol. 51, No. 4, Nov. 2010, 4 pp. [cited by applicant]
Missero et al., “Crosstalk among p53 family members in cutaneous carcinoma,” Experimental Dermatology, vol. 23, No. 3, Mar. 2014, 4 pp. [cited by applicant]
Niendorf et al., “Cutaneous melanoma: family screening and genetic testing,” Dermatologic Therapy, vol. 19, No. 1, Jan. 2006, 8 pp. [cited by applicant]
Rhodes et al., “Risk factors for cutaneous melanoma, A practical method for recognizing predisposed individuals,” Journal of the American Medical Association (JAMA), vol. 258, No. 21, Dec. 1987, 9 pp. [cited by applicant]
Roh et al., “Molecular Mechanisms of Green Tea Polyphenols with Protective Effects against Skin Photoaging,” Critical Reviews in Food Science and Nutrition, vol. 57, No. 8, accepted author version posted online Jun. 201… [cited by applicant]
Yokogawa et al., “Imiquimod attenuates the growth of UVB-induced SCC in mice through Th1/TH17 cells,” Molecular Carcinogenesis, vol. 52, No. 10, Oct. 2013, 17 pp. [cited by applicant]
Zhu et al., “Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells,” Gastroenterology, vol. 133, No. 1, Jul. 2007, 13 pp. [cited by applicant]
Zykova et al., “The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis,” EbioMedicine, vol. 18, 2017, 10 pp. [cited by applicant]
International Preliminary Report on Patentability from International Application No. PCT/US2018/036720, mailed Dec. 19, 2019, 7 pp. [cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/US2018/036720, mailed Sep. 7, 2018, 9 pp. [cited by applicant]